New antifungal agents: Voriconazole and caspofungin;Nouveaux antifongiques: Voriconazole et caspofungine

Archives de Pediatrie

Volumn 10, Issue SUPPL. 5, 2003, Pages

  Dupont, B ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Antibiotics, peptid; Antifungal agents; Caspofungin; Thiazoles

Indexed keywords

AMPHOTERICIN B; ANTIVITAMIN K; ASTEMIZOLE; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CARBAMAZEPINE; CASPOFUNGIN; CIMETIDINE; CISAPRIDE; CYCLOSPORIN; DIGOXIN; ERGOT ALKALOID; INDINAVIR; MACROLIDE; MYCOPHENOLIC ACID; PHENYTOIN; PREDNISONE; QUINIDINE; RANITIDINE; RIFABUTIN; RIFAMPICIN; SULFONYLUREA DERIVATIVE; TACROLIMUS; TERFENADINE; VORICONAZOLE; ANTIFUNGAL AGENT; CYCLOPEPTIDE; PEPTIDE; PYRIMIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ASPERGILLOSIS; ASPERGILLUS; BLASTOMYCES DERMATITIDIS; CANDIDA; CANDIDIASIS; COCCIDIOIDES IMMITIS; CONFERENCE PAPER; CRYPTOCOCCUS NEOFORMANS; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; FEBRILE NEUTROPENIA; FRANCE; FUSARIUM; HIGH RISK POPULATION; HISTOPLASMA CAPSULATUM; HUMAN; MYCOSIS; NEUTROPENIA; SACCHAROMYCES CEREVISIAE; SCEDOSPORIUM; SPOROTHRIX SCHENCKII; THRUSH; CHILD; DRUG INTERACTION; METABOLISM; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CHILD; DRUG INTERACTIONS; HUMANS; PEPTIDES; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 0346847743     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)90630-0     Document Type: Conference Paper

References (31)

1. Pfaller MA, Diekema DJ, Jones RN, Sader HS, Fluit AC, Hollis RJ, et al. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluoconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobial surveillance program. J Clin Microbiol 2001; 39: 3254-9.
2. Ruhnke M, Schmidt-Westhausen A, Trautmann M. In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and-resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 1997; 41: 575-7.
3. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998; 36: 198-202.
4. Manavathu EK, Cutright JL, Loebenberg D, Chandrasekar DH. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole, and posaconazole (SCH-56592). J Antimicrob Chemother 2000; 46: 229-34.
5. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001; 39: 954-8.
6. Hoffman HL, Rathbun RC. Review of the safety and efficacy of voriconazole. Expert Opin Investig Drugs 2002; 11: 409-29.
7. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
8. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, et al. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J 2002; 21: 240-8.
9. Ally R, Schurmann D, Kreisel W, Carosi G, Aguirrebengoa K, Dupont B, et al. A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients. Clin Infect Dis 2001; 33: 1447-54.
10. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffali J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346: 225-34.
11. Hegener P, Troke PF, Fatkenheuer G, Diehl V, Ruhnke M. Treatment of fluconazole-resistant candidiasis with voriconazole in patients with AIDS. AIDS 1998; 12: 2227-8.
12. Ostrosky-Zeichner L, Oude Lashof AML, Kullberg BJ, Rex JH. Voriconazole for salvage treatment of invasive candidiasis: experience from open-label protocols. 40th Meeting IDSA, Chicago, 2002.
13. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
14. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002; 34: 563-71.
15. Lorthorlary O, Mouas-Dupuy H, Dupont B, Lutsar I, Fain O. Voriconazole for bone aspergillosis a world wide experience of 19 cases. 43th ICAAC, Chicago, 2003, abst: M929, p. 450-451.
16. Troke PF, Schwartz S, Ruhnke M, Ribaud P, Corey L, Driscole T. et al. Voriconazole therapy in 86 patients with CNS aspergillosis: a retrospective analysis. 43th ICAAC, Chicago, 2003, abst: M1755, p. 476.
17. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
18. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36: 1122-31.
19. Reis A, Sundmacher R, Tintelnot K, Agostini H, Jensen HE, Althaus C. Successful treatment of ocular invasive mould infection (fusariosis) with the new antifungal agent voriconazole. Br J Ophtalmol 2000; 84: 932-3.
20. Barrizal K, Gill CJ, Abruzzo GK, Flattery AM, Kong L, Scott PM, et al. In vitro preclinical evaluation studies with the echinocandin anti-fungal MK-0991 (L-743,872). Antimicrob Agents Chemother 1997; 41: 2326-32.
21. Abruzzo GK, Flattery AM, Gill CJ, Kong L, Smith JG, Pikounis VB, et al. Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob Agents Chemother 1997; 41: 2333-8.
22. Abruzzo GK, Gill CJ, Flattery AM, Kong L, Leighton C, Smith JG, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Anfimicrob Agents Chemother 2000; 44: 2310-8.
23. Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36: 1445-57.
24. Dupont B. Caspofungine: nouvel antifongique de la classe des echinocandines. J Mycol Med 2002; 12: 1S20-1S24.
25. Letscher-Bru V, Herbrecht R. Caspofungin: the first representative of a new antifungal class. J Antimicrob Chemother 2003; 51: 513-521.
26. Villanueva A, Arathoon EG, Gotuzzo E, Berman RS, DiNubile MJ, Sable CA. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis 2001; 33: 1529-35.
27. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, Dinnubile MJ, Sable CA. A randomized, double-blind, multicenter study of caspofungin versus amphotericin B for the treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agents Chemother 2002; 46: 451-7.
28. Villanueva A, Gotuzzo E, Arathoon E, Noriega LM, Kartsonis N, Lupinacci RJ, et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med 2001; 113: 294-9.
29. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 2002; 347: 2020-9.
30. Maertens J, Raad I, Petrikos G, Selleslag D, Petersen FB, Sable CA, et al. Update of the multicenter, noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: an analysis of 90 patients. 40th ICAAC, San Diego, CA, USA, 2002, abstr: M868, p. 388.
31. Walsh T, Sable C, de Pauw B, Donowitz G, Maertens J, Baden L, et al. A randomized double-blind, multicenter trial of caspofungin versus liposomal amphotericin B for empirical antifungal therapy of persistantly febrile neutropenic patients, 43th ICAAC, Chicago, 2003, abst: M1761, p. 477.